If panic sets in, it can make any situation worse than it already is. Unfortunately, the turn taken by the Kovid epidemic in India seems to be doing just that. A terrible spike of infections and a kind of tremor before the buckling of our health infrastructure under their weight. The term for the new triple-mutant variant of SARS-Cove-2 in West Bengal is also believed to include horrible mutations found in South African and Brazilian species, raising concerns about the effectiveness of vaccines designed before the virus became its genetic makeup. This week is full of cases where those who have been fully vaccinated have been tested positive by Kovid. Strictly speaking, it takes some time for one’s body to develop antibodies that prevent covid, and the purpose of the vaccine is to prevent illness, not to provide foolproof insulation from pathogens. However, there is growing controversy over the immunity that vaccines provide. On Wednesday, the Indian Council of Medical Research (ICMR) sought to quell the suspicions. But some of these will continue, the hair on this jab will be split and against one race or another. Such confusion should not be translated into jab contraction.
According to the ICMR, it is very rare for a virus to infect a job’s shield. According to the findings of this government research institute, of the 1.7 million people who received two prescribed doses of covaxin, it was developed in conjunction with Bharat Biotech, which tested only 0.04% or positive; And of the 15.7 million who took two shots of the Kovishield, made by the Serum Institute of India, only 0.03% were. Its single-dose numbers also indicate a small probability of catching a bug-post-job. This dataset, however, is taken from a statistical compilation, rather than from a clearly designed clinical study to test how well our vaccines work against specific mutants. Sure, not all job recipients have been tested, so the percentages quoted are not conclusive. They are common observations in many social groups. As for the laboratory studies conducted by ICMR and the National Institute of Virology, it has not yet been disclosed. It is also unclear whether these results will be available for a global peer review. As noted by ICMR, apart from the Indian double mutant, the South African, Brazilian and British variants of the virus were examined. It also states that covaxin has been found to work “well” against these. The statement was taken by some as a symbol of Kovacsin’s dominance over the Kovshield, and the ability to prevent the South African race has recently been disputed.
The open market for vaccines will soon be able to give people their preferences, there is no information at this stage, which will allow us to take accurate calls from which variant can best protect us. True, genetic research suggests that SARS-COV-2 may have a strange possibility of developing beyond the current range of diseases, but it is uncertain whether this has happened. However, the fog hanging over this issue requires clear communication through ICMR and greater vigilance over various mutations so that we can not fall behind the curve of scientific knowledge and receive vaccines quickly if needed. We do not know when new species will emerge. What we do know is that vaccines are big. They drastically reduce the overall probability of falling victim to Kovid-19. This is reason enough to be jabbed.